-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Esperion Therapeutics, Raises Price Target to $5

Benzinga·03/13/2026 10:36:32
Listen to the news
Citizens analyst Jason N. Butler maintains Esperion Therapeutics (NASDAQ:ESPR) with a Market Outperform and raises the price target from $4 to $5.